Although the term "accountable care organization" (ACO) may not be here to stay, value-based organizations are here to stay based on the direction CMS is headed, said Jeb Dunkelberger, vice president of accountable care services at McKesson and clinical & commercial operations at ACO Partner.
Although the term "accountable care organization" (ACO) may not be here to stay, value-based organizations are here to stay based on the direction CMS is headed, said Jeb Dunkelberger, vice president of accountable care services at McKesson and clinical & commercial operations at ACO Partner.
Transcript (slightly modified)
Are ACOs here to stay? Or are they a stepping stone to the next delivery model?
I think that when you look at ACOs, I don’t know if the vernacular is here to stay. I like to call them value-based organizations because as I look at an ACO, I look at somebody who is unifying patients, providers, and stakeholders. I’ll look at somebody who’s aligning incentives in a way that is increasing quality of care and decreasing avoidable cost. And I look at somebody who at the end of the day buys into the fact that if I increase the patient population health, I can decrease overall cost.
I don’t know if it’s going to be an ACO. But there’s no question I believe it’s here to stay. I think when you look at comprehensive primary care plus (CPC plus), when you look at MACRA [Medicare Access and CHIP Reauthorization Act], when you look at APMs [alternative payment models], Medicare has done a beautiful job showing us where they’re going. CMS has done an amazing job saying, ‘here’s the direction we’re taking’ and I think it’s our job to then read off that, look at payers in the market—where are they going with it? Look at the commercial versus public ACOs. I mean there is no question that we are moving forward.
There’s some great analysis in the market right now that’s showing the amount of patients that are being covered by ACOs and how quickly it’s growing and I think that although we may not call it an ACO depending upon who wins the general election, I think value-based organizations are here to stay.
A meta-analysis showed that control group outcomes in psilocybin trials for depression were significantly weaker than those in selective serotonin reuptake inhibitor (SSRI) and esketamine trials, suggesting that psilocybin’s large observed treatment effects may be inflated by methodological factors such as functional unblinding and expectancy bias.
Read More
Trump Directs Pharma Companies on Cutting Drug Prices Under Most-Favored-Nation Order
July 31st 2025President Donald Trump has sent letters to pharmaceutical companies, aiming to compel them to lower drug prices in the US to match the lowest prices offered in other developed nations, a move that could significantly reduce costs and disrupt the current system of pharmacy benefit managers.
Read More
Legal Navigation Services Key to Addressing Disparities in Cancer Care
July 31st 2025A significant number of patients with cancer, caregivers, and health care professionals face significant disparities in legal issues, with the most common needs revolving around health insurance, finances, employment, and disability insurance.
Read More